LY294002

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

For research use only.

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

LY294002 Chemical Structure

CAS No. 154447-36-6

Selleck's LY294002 has been cited by 1409 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Targets
CK2 [5]
(Cell-free assay)
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
(Cell-free)
98 nM 0.5 μM 0.57 μM 0.97 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 cells NHK1U5FHfW6ldHnvckBie3OjeR?= MVLJcohq[mm2aX;uJI9nKEircz30ZYdo\WRiYn;2bY5mKFCLM1ug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0yOCEQvF2u NVnsVHYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC5PVg{PTFpPkGwPVk5OzVzPD;hQi=>
HeLa cells NYHBNJdySmmwZHnu[{Bi\m[rbnn0fUBie3OjeR?= M4[5c2JqdmSrbnegZYZncW6rdImg[o9zKFCLMz3rbY5ie2ViaYPvcIF1\WRiZoLvcUBJ\UyjIHPlcIx{NCCNaU22JO69VQ>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O|A9N2F-
HeLa cells Mn3RSpVv[3Srb36gZZN{[Xl? MmHoTY5pcWKrdHnvckBw\iCvVF;SJJBzd3SnaX6gbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy|LDDJR|UxRTJwNTFOwG0v MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O|A9N2F-
HeLa (human carcinoma) cells. MVHGeY5kfGmxbjDhd5NigQ>? Mo[5TY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NCCLQ{WwQVEvPCEQvF2u M3T1R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
human PC3 cells MX3Qdo9tcW[ncnH0bY9vKGG|c3H5 MWeyOUDPxE1? MWWxNlAhcA>? Mm\kRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNiYYSgNlUhfU1iYX\0[ZIhOTJyIHjyd{BjgSCPVGSgZZN{[XlicnXsZZRqfmVidH:gSG1UVw>? NUC4NZRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[2PFAyPTlpPkG2OlgxOTV7PD;hQi=>
human BJ cells NWjiSGNNTnWwY4Tpc44h[XO|YYm= NHHBTJczPSEQvF2= MlfWNkBp MnPLRYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=> M{fYfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O|A5PTxxYU6=
human BJ cells MVLGeY5kfGmxbjDhd5NigQ>? MUWyOUDPxE1? NFLoUIMzKGh? MUXJcohq[mm2aX;uJI9nKFCLM1ugd4lodmGuaX7nJIlvKFCGR1[td5RqdXWuYYTl[EB{\XK3bTDzeIFzfmWmIHj1cYFvKEKMIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheGyjc33p[EBGT0[SL2DIJIRwdWGrbjDv[kBCc3RiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFitSWdHWCC{ZXTpd5RzcWK3dHnvckB1dyCybHHzcYEhdWWvYoLhcoUh[XRiMkWgeW0hfHKnYYTl[EAzKGi{czDi[YZwemViUFTHSkBkcGGubHXu[4Uh[nliY3;u[o9k[WxibXnjdo9{[2:yeR?= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd4N{C4OUc,OTZ5NkewPFU9N2F-
mouse mast cells NW\ib25NTnWwY4Tpc44h[XO|YYm= MXOyNEDPxE1? NWPqWGtSUW6qaXLpeIlwdiCxZjDTR2YucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDtZZN1KGOnbHzzJIF1KDJyIN88US=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
THP1 cells MYLGeY5kfGmxbjDhd5NigQ>? NEDydmVKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBkcGWvb4ThfIl{KG:oIGTIVFEh[2WubIOsJGlEPTB;M{eg{txONg>? NY\TcJdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O|g6PzR{PD;hQi=>
mouse Raw264 macrophage MmXDSpVv[3Srb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKEN3YT3t[YRq[XSnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDtc5V{\SCUYYeyOlQhdWGlcn;wbIFo\SxiSVO1NF0yOCEQvF2u MoHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O|QzRC:jPh?=
THP1 cells M4nQdmZ2dmO2aX;uJIF{e2G7 NITJXplKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBVUFBzIHPlcIx{NCCLQ{WwQVEvPjVizszNMi=> NWTCVWNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O|g6PzR{PD;hQi=>
THP1 cells MnXQSpVv[3Srb36gZZN{[Xl? MkCxTY5pcWKrdHnvckBw\iCVQ1[xMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlAyKM7:TT6= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
human A375 cells NVTrbIpPWHKxbHnm[ZJifGmxbjDhd5NigQ>? NUL1e|hiPDZiaB?= NHfXO3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|Uh[2WubIOgZYZ1\XJiNE[gbJJ{NCCLQ{WwQVgvPCEQvF2u MnPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyNEmyOFgoRjF5MES5NlQ5RC:jPh?=
HeLa cells MW\GeY5kfGmxbjDhd5NigQ>? MljjTY5pcWKrdHnvckBw\iCDWD23OVA{KGKrbnTpcochfG9icnXjc41jcW6jboSgVIxsOyCneIDy[ZN{\WRiaX6gTIVN[SClZXzsd{BjgSCZZYP0[ZJvKGKub4SsJGlEPT1|IN88UU4> NXHIfI1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexN|UzPDhpPkG3NVM2OjR6PD;hQi=>
human SW480 cells M4n4RmZ2dmO2aX;uJIF{e2G7 MYGyNEDPxE1? NV3obnMyOjRiaB?= NF;3VmVF\WO{ZXHz[UBqdiC|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIh2dWGwIGPXOFgxKGOnbHzzJIF1KDJyIIXNJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz NFXIUI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S3Nlk3Oid-MUe0O|I6PjJ:L3G+
human A375 cells Mo\5VJJwdGmoZYLheIlwdiCjc4PhfS=> Ml;qTY5pcWKrdHnvckBw\iC|ZYL1cU1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iQUO3OUBk\WyuczygTWM2OD16LkSg{txONg>? M3znXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCxO|M6Lz5zN{[wNVc{QTxxYU6=
human A2780 cells NHm1N4JCeG:ydH;zbZMh[XO|YYm= NV;0TXRQOiEQvF2= MUCxNkBp MX\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHPpd5Bt[XSrbj3y[ZNqe3SjboSgbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSWu2IHzleoVtKGG2IEKgeW0h[W[2ZYKgNVIhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZMv NIe5WIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFAyQCd-MUe2PFQxOTh:L3G+
human H4 cells M1:4[mZ2dmO2aX;uJIF{e2G7 MX6yJIg> MYnE[YNz\WG|ZTDpckBHYV[HLWLGVEshfmW|aXPs[UBqdnSnboPpeJkheGW{IHPlcIwhcW5iaIXtZY4hUDRiY3XscJMh[W[2ZYKgNkBpenNicnXsZZRqfmVidH:gZ49vfHKxbB?= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB{NEW4OEc,OThyMkS1PFQ9N2F-
Sf9 cells MXXGeY5kfGmxbjDhd5NigQ>? NVK4[JRpUW6qaXLpeIlwdiCxZjDDT|Ih\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD14Lkmg{txONg>? M{jadFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{KxO|E3Lz5zOEOyNVcyPjxxYU6=
rat RBL2H3 cells M2fodWZ2dmO2aX;uJIF{e2G7 NHm1fFNKdmirYnn0bY9vKG:oIFGyN|E5Py2rbnT1Z4VlKGSnZ4LhcpVt[XSrb36gbY4hemG2IGLCUFJJOyClZXzsdy=> M4f6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{K4O|E3Lz5zOEOyPFcyPjxxYU6=
human U87MG cells MVLGeY5kfGmxbjDhd5NigQ>? MoDiTY5pcWKrdHnvckBw\iCJU1uzMYJmfGFiaX6gbJVu[W5iVUi3UWch[2WubIOgZpkhTUyLU1GsJGlEPTB;OD6xJO69VS5? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN2NU[wPUc,OTh|NEW2NFk9N2F-
human H460 cells MV;GeY5kfGmxbjDhd5NigQ>? Mn3IN|Ah|ryP NX7UXIt6UW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKEh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOgRYt1KHCqb4PwbI9zgWyjdHnvckBifCCVZYKgOFc{KHWyIITvJFMxKHWP NYmzOFlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NFE3ODFpPkG4OVAyPjBzPD;hQi=>
human U251HRE cells M{TFOGZ2dmO2aX;uJIF{e2G7 MmfVTY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmIMTDhZ5RqfmG2aX;uJIlvKGi3bXHuJHUzPTGKUlWgZ4VtdHNiYomgZ4VtdCCkYYPl[EBz\XCxcoTldkBo\W6nIHHzd4F6 M1nZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUCxOlAyLz5zOEWwNVYxOTxxYU6=
human 184B5 cells M3;2XGN6fG:2b4jpZ:Kh[XO|YYm= NUDXb2tUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTh2QkWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUO5MlM4KM7:TT6= M4nyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-468 cells MlOzR5l1d3SxeHnjxsBie3OjeR?= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHL5JHNTSiCjc4PhfUwhUUN3ME2xNE41KM7:TT6= Mli0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-468 cells MnGxR5l1d3SxeHnjxsBie3OjeR?= MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD16LkKg{txONg>? M3XqcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
MDA-MB-231 cells MnTGR5l1d3SxeHnjxsBie3OjeR?= NX:1bI56S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:Pi55MTFOwG0v MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-468 cells MXjDfZRwfG:6aXRCpIF{e2G7 NX7hZ4VnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZnwxIxiSVO1NF01Njd4IN88UU4> NWDqTWE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells M4XubGN6fG:2b4jpZ:Kh[XO|YYm= MoXER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpckBxemW|ZX7j[UBw\iBzMDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYmsJGdKPTB;ND6zOUDPxE1w MnLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-231 cells MVjDfZRwfG:6aXRCpIF{e2G7 MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuJJBz\XOnbnPlJI9nKDJyIN88UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYmsJGdKRTNwM{Kg{txONg>? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MCF7 cells NFXTR2dEgXSxdH;4bYPDqGG|c3H5 MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m9N{4yPiEQvF2u NVK4TVByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells MYrDfZRwfG:6aXRCpIF{e2G7 MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2zMlA5KM7:TT6= NUjQcIJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells NH3M[4xEgXSxdH;4bYPDqGG|c3H5 MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJO69VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9Nk43OyEQvF2u NE[1dlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
Sf21 cells MWfGeY5kfGmxbjDhd5NigQ>? MkOwTY5pcWKrdHnvckBw\iCvb4Xz[UBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoMkGgZ4VtdHNuIFnDOVA:OC53IN88UU4> NFGyVHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0PFI3QSd-MUm3OFgzPjl:L3G+
Sf9 cells NXHpe4xG\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7 NIfn[VdKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIJ6KG[udX;y[ZNk\W62IIDvcIFzcXqjdHnvckBie3OjeR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N|E9N2F-
Sf9 cells MVvGcJVwemW|Y3XueEBxd2yjcnn6ZZRqd25iYYPzZZk> NVHoS4RSUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO|YYmsJGlEPTB;MD61OUDPxE1w MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N|E9N2F-
human IGROV1 cells M2GxdGZ2dmO2aX;uJIF{e2G7 MVSyOEBp M2Gxc2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgOUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 M4TS[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkG2NVUyLz5{MUKxOlE2OTxxYU6=
human IGROV1 cells MkXmSpVv[3Srb36gZZN{[Xl? NIfibpAzPCCq MmG0R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTWdTV1ZzIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMTDwbIF{\SCjdDCxJIZwdGRiSVO1NEBi\nSncjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzNkG1NUc,OjF{MU[xOVE9N2F-
human IGROV1 cells MX;GeY5kfGmxbjDhd5NigQ>? M2[3U|I1NzR6IHi= MX3Jcohq[mm2aX;uJI9nKFCLM1uvRYt1KGmwIHj1cYFvKEmJUl;WNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCleXPsbY4hTDFibHX2[Ywh[XRiMTD0c{A2KHSrbXXzJGlEPTBiYX\0[ZIhOjRidH:gOFghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NUTicYpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human IGROV1 cells MXrGeY5kfGmxbjDhd5NigQ>? Mo[yNlQwPDhiaB?= MnTOTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MlL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human HCT116 cells MUfDfZRwfG:6aXRCpIF{e2G7 NF\yfWE4OiCq NWi3fVJ4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PTZwMEGg{txONg>? NWL0UZVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFUzPTBpPkKxPVQ2OjVyPD;hQi=>
human KB cells MYnDfZRwfG:6aXRCpIF{e2G7 M{\RTVczKGh? NWP2OGs1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20OE44PiEQvF2u M4TzfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUS1NlUxLz5{MUm0OVI2ODxxYU6=
HUVEC NIfVOYZHfW6ldHnvckBie3OjeR?= NWXVWWJCOTBvMkWg{txO MnLqN|AhdWmw MmjqTY5pcWKrdHnvckBw\iCWTl\hcJBp[S2|dHnteYxifGWmIHj1cYFvKEmFQV2tNUBxem:vb4TldkBi[3Srdnn0fUBmgHC{ZYPz[YQhcW5iSGXWSWMh[XO|ZYPz[YQh[XNiYnX0ZU1o[WyjY4Tvd4ll[XOnIHHjeIl3cXS7IHH0JFExKHSxIEK1JJVOKHC{ZYTy[YF1\WRiZn;yJFMxKG2rboOgZoVnd3KnIGTOSoFteGijIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYm= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{NkSxNEc,OjJyMk[0NVA9N2F-
HUVEC NHHWWmNHfW6ldHnvckBie3OjeR?= NX70dmtmOTBvMkWg{txO MVSxOkBp M3LFWWlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDJR2FONTFibWLORUBmgHC{ZYPzbY9vKGmwIFjVWmVEKGG2IEGwJJRwKDJ3IIXNJJBz\XS{ZXH0[YQh\m:{IEG2JIhzeyCkZX\vdoUhXE6IYXzwbIEh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFYhcHK|IHL5JHJVNVCFUjDhcoFtgXOrcx?= NX;0cYs{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlY1OTBpPkKyNFI3PDFyPD;hQi=>
human HCT116 cells M4LDcmZ2dmO2aX;uJIF{e2G7 NUDi[IlPOTBizszN MXzJcohq[mm2aX;uJI9nKEGtdDDlfJBz\XO|aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjdDCxNEB2VSCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz MknTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human HCT116 cells NF\o[pJHfW6ldHnvckBie3OjeR?= MmHYNVAh|ryP M4r6e2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIFixNFQ4WiCvdYThcpQhcW5iaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=> MoHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human HCT116 cells MUHGeY5kfGmxbjDhd5NigQ>? MV6xNEDPxE1? MVLJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDifUBqdW23bn;icI91KGGwYXz5d4l{ MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells NIPaSGhHfW6ldHnvckBie3OjeR?= MnO4NVAh|ryP Mom0NVAhdWmw NX;XNGJCUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgTFExPDeUIH31eIFvfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> NEXTOVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells NEfKemFHfW6ldHnvckBie3OjeR?= M170bFExKM7:TR?= NX31SJBSOTBibXnu NELnXHNKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDIR3QyOTZiY3XscJMhfXOrbnegX|MzWF2DVGCgZZQhOTBidV2gZYZ1\XJiMUCgcYlvew>? NEHkTlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYm0PEBp MUPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncnX4dJJme3OrbnegVGk{U2GucHjhJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Nj63JO69VS5? M{nyd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWC1PIppPDhiaB?= M1TqZmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQCEQvF2u NGTIUZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells Ml;2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1nQZ|Q5KGh? NXPI[nhxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NT6zJO69VQ>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human A549 cells NHPMZVVEgXSxdH;4bYPDqGG|c3H5 MlPRO|IhcA>? Mlf2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5 M4XpZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
human PC3 cells MX\DfZRwfG:6aXRCpIF{e2G7 M1mwdVczKGh? NWftWXZ2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OlEvOzVizszNMi=> NX\m[ZdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFA5PTFpPkKyOFgxQDVzPD;hQi=>
human HL60 cells MULDfZRwfG:6aXRCpIF{e2G7 M{jLTFczKGh? M3TR[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25Mlk1KM7:TT6= Mny2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEC4OVEoRjJ{NEiwPFUyRC:jPh?=
Sf21 cells MVHGeY5kfGmxbjDhd5NigQ>? M1:3bGlvcGmkaYTpc44hd2ZibX;1d4Uhf2muZDD0fZBmKFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gV4YzOSClZXzsd{Bkdy2neIDy[ZN{cW6pIF6teIVzdWmwYXygTIl{NXSjZ3fl[EBpfW2jbjDwPFViKHW|aX7nJGwu[WyyaHGtdIhwe3CqYYTp[JltcW6xc3n0c4whe3Wkc4TyZZRmKGK7IGTMR{Bj[XOnZDDwbI9{eGixcjDpcYFocW6pLDDJR|UxRTBwNTFOwG0> NFvuW2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWyNFY{OCd-MkK1NlA3OzB:L3G+
HEK293 cells MY\GeY5kfGmxbjDhd5NigQ>? NV:yTZVjOS53IHi= MkTNSIl{eGyjY3Xt[Y51KG:oIGuzTH1NW0RiZoLvcUBpfW2jbjC1THQ3KHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNU42KGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\w>? M3\z[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUO3NVU{Lz5{MkWzO|E2OzxxYU6=
human H1299 cells M1rpeGZ2dmO2aX;uJIF{e2G7 NESxOYcxNjFvM{Cg{txO MUmyOEBp NFHmcIJKdmS3Y4Tpc44hd2ZiSl7LMY1m\GmjdHXkJGNJV1BiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MnrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
human H1299 cells M3jZSGZ2dmO2aX;uJIF{e2G7 MVWwMlEuOzBizszN M3jaWVI1KGh? M3voVGlv\HWldHnvckBw\iCGUkWg[ZhxemW|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NX31XXVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells MUXGeY5kfGmxbjDhd5NigQ>? NVfkdFh5OC5zLUOwJO69VQ>? Mn7xNlQhcA>? MYTEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjCxNFAhfWdxbXygWHJCUUxiYX7kJHBKO0tiaX7obYJqfG:{IFzZNlk1ODB{ NXv6dVh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells NFfCeHVHfW6ldHnvckBie3OjeR?= NFfHeYUxNjFvM{Cg{txO M2XBSVI1KGh? MXHEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NXfLRXYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
MDA-MB-231 cells Mmm3R4VtdCCrbo\hd4lwdiCjc4PhfS=> M{XzXVI1KGh? NXnuc|VmUW6qaXLpeIlwdiCxZjDldIl1cGWuaXHsJIdzd3e2aDDmZYN1d3JvaX7keYNm\CClZXzsJI1q\3KjdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJJBz\S2rbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBk\WyuIHnueoF{cW:wIHHzd4F6NCCLQ{WwQVAvOzhizszNMi=> NFr3enA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwOFExQCd-MkK4NFQyODh:L3G+
human LNCAP cells NVjLPFQyTnWwY4Tpc44h[XO|YYm= MYewMlEuOzBizszN Mn7hNlQhcA>? MlPPSI94dnKnZ4XsZZRqd25ib3[gd5Vzfmm4aX6g[ZhxemW|c3nvckBqdiCqdX3hckBNVkODUDDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? M13hcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN|E3Lz5{MkizNlMyPjxxYU6=
human LNCAP cells M2DiTWZ2dmO2aX;uJIF{e2G7 MlnxNE4yNTNyIN88US=> NHP2WGw{OCCvaX6= MmTxTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB|MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NWmwTGR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N|I{OTZpPkKyPFMzOzF4PD;hQi=>
human PC3 cells NYm3V3NOTnWwY4Tpc44h[XO|YYm= Ml\yOVAh|ryP MofYPEBp NG\tVm1KdmS3Y4Tpc44hd2ZicEKxJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCqdX3hckBRSzNiY3XscJMh[XRiNUCgeW0hcW6ldXLheIVlKG[xcjC4JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s MlnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OUi0O|IoRjJ{OUm4OFczRC:jPh?=
human BT474 cell MlLvVJJwdGmoZYLheIlwdiCjc4PhfS=> M33Rb|czKGh? MknoTY5pcWKrdHnvckBw\iCqdX3hckBDXDR5NDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrc,-8kEBKSzVyPUKwMlch|ryPLh?= MkTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ|NEGwNFA2RC:jPh?=
human PC3 cell MkTlVJJwdGmoZYLheIlwdiCjc4PhfS=> MmKzO|IhcA>? MlTOTY5pcWKrdHnvckBw\iCqdX3hckBRSzNiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSC|cHXjeJJweGixdH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:OTJwMTFOwG0v NIryVWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNFAxPSd-MkO0NVAxODV:L3G+
human PC3 cells MnzZSpVv[3Srb36gZZN{[Xl? M2fV[|MxKG2rbh?= MlPkTY5pcWKrdHnvckBw\iCSSUPLJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KHOncnnu[UA1PzNiYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhUUN3ME2xMlPPxE1w MljNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ|NEGwNFA2RC:jPh?=
human MGC803 cells MU\GeY5kfGmxbjDhd5NigQ>? NEPFTYczPSEQvF2= MXS0PEBp MoXzR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUWdEQDB|IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFI2KHWPIHHmeIVzKDR6IHjyd{B2e2mwZzDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHHmeIVzKDR6IHjyd{BjgSCobH;3JIN6fG:vZYTldkBz\WyjdHn2[UB1dyClb370do9t M1;2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUG5PFY6Lz5{NEGxPVg3QTxxYU6=
mouse RAW264.7 cells NGXIXoFHfW6ldHnvckBie3OjeR?= M1K4dFI2KM7:TR?= MWmyNEBp Mm\OTY5pcWKrdHnvckBw\iCSSUPLM2FMXCCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKGmQT2OgdJJwfGWrbjDlfJBz\XO|aX;uJIF1KDJ3IN88UUBi\nSncjCyNEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NUfLTVQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVk3OTZpPkK0Nlk6PjF4PD;hQi=>
human A549 cells M{PHTnBzd2yrZnXyZZRqd25iYYPzZZk> MWO3NkBp M2fCbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD16Mj6zNkDPxE1w NHS5fW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
human HuH7 cells MXrQdo9tcW[ncnH0bY9vKGG|c3H5 NWXpTVg5PzJiaB?= Mlv4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKdVi3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTZ5LkG4JO69VS5? NIfNTFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
human HCT116 cells M4nIOXBzd2yrZnXyZZRqd25iYYPzZZk> Mn;OO|IhcA>? MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13MT64NkDPxE1w NGXCU489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
human HL60 cells M2T4OnBzd2yrZnXyZZRqd25iYYPzZZk> M32xUVczKGh? MnLtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTF6LkSzJO69VS5? MmraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO|g4RC:jPh?=
Sf9 cells MkC0SpVv[3Srb36gZZN{[Xl? NICyZnBKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgbJVu[W5iQ1uyJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVAhRSB4Lkmg{txONg>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODl7OEO1NUc,OTB7OUizOVE9N2F-
HeLa cells M3\wZ2Z2dmO2aX;uJIF{e2G7 NHX6[WlKdiC4aYTyc{BqdmirYnn0bY9vKG:oIFTORU1l\XCnbnTlcpQheHKxdHXpckBscW6jc3WoSG5CNVCNKTDmdo9uKEinTHGgLIh2dWGwIHPhdoNqdm:vYTmgZ4VtdHNwLDDJR|UxKD1iMT60JO69VS5? M{LGOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUSxN|M6Lz5zMkm0NVM{QTxxYU6=
HeLa cells NGHhUJBHfW6ldHnvckBie3OjeR?= NGrUXlVKdmirYnn0bY9vKG:oIFTORUBl\XCnbnTlcpQheHKxdHXpckBscW6jc3WgbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy|LDDJR|UxKD1iMT61JO69VS5? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O|A9N2F-
Sf21 cells MmriSpVv[3Srb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1vi[ZRiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{1qdm[nY4Tl[EBU\jJzIHPlcIx{NCCLQ{WwJF0hOC57IN88UU4> NWjDTIVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O|Q5OjZ7PD;hQi=>
Sf21 cells NYHJV2NFTnWwY4Tpc44h[XO|YYm= MojRTY5pcWKrdHnvckBw\iCkb4\pcoUhemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy|LDDJR|UxKD1iNzFOwG0v NV2yRmJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O|Q5OjZ7PD;hQi=>
HeLa cells NIX5V3FHfW6ldHnvckBie3OjeR?= NELSU2VC[3Srdnn0fUBifCCSSUPLJIlvKGi3bXHuJGhmVGFiY3XscJMh[nliRVzJV2EtKEWFNUCgQUAyNjVizszNMi=> Mm\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByOUKzNlMoRjJyMEmyN|I{RC:jPh?=
Sf21 cells NIHxZo9HfW6ldHnvckBie3OjeR?= MXnJcohq[mm2aX;uJI9nKFCLM1vk[Yx1[SCneIDy[ZN{\WRiaX6gZ4VtdHNiY3:t[ZhxemW|c3nu[{BPNXSncn3pcoFtKEircz30ZYdo\WRiaIXtZY4heDh3YTD1d4lv\yCOLXHsdIhiNXCqb4PwbIF1cWS7bHnuc5NqfG:uIIP1ZpN1emG2ZTDifUBVVENiYnHz[YQheGixc4Doc5IhcW2jZ3nu[{whUUN3MDC9JFAvPTdizszNMi=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV{ME[zNEc,OjJ3MkC2N|A9N2F-
Sf21 cells NInDNm1HfW6ldHnvckBie3OjeR?= Mly5TY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhWEl|S3LleIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NEA:KDBwOUeg{txONg>? NYHLO3VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
HL60 cells M4HubWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1Tk[|Mh\GG7cx?= MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF2IN88UU4> NUHve49VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
U937 cells NXv5XFZmSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MUCzJIRigXN? M3nPbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMUSg{txONg>? NU\LRVJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
Jurkat cells MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVGwSXBROyCmYYnz MlOyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCMdYLrZZQh[2WubIOgcYVie3W{ZXSgZYZ1\XJiMzDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEKyJO69VS5? NU\rNXdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
K562 cells M1\QR2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NUjt[XBzOyCmYYnz NVfPRnFSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTBiPTCzPEDPxE1w MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
U266 cells NH3NSGNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NX;PSIRiOyCmYYnz MojJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXMk[2JINmdGy|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVAhRSB2NjFOwG0v NIDFb|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
MDA-MB-231 cells M{TqSmFvfGmvaXfyZZRwenliYYPzZZk> MWGyOEBpenN? MX7BcpRqdWmpcnH0c5J6KGGldHn2bZR6KGGpYXnud5QhTUeIIHnu[JVk\WRiY3jlcY91[XirczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIDy[Ylv[3WkYYTl[EBnd3JiMkSgbJJ{KG[xbHzve4VlKGK7IFXHSkBi\GSrdHnvckBnd3JiMz61JIhzeyCkeTDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxKD1iMD6zPEDPxE1w NIjVc4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W5PFI{Pyd-Mke1PVgzOzd:L3G+
MDA-MB-231 cells MoewRY51cWmwdnHzbZZmKGG|c3H5 MlXYN{42KGi{cx?= NX;DOZk6SW62aXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDj[YxtKGmwdnHzbY9vKGGodHXyJFMvPSCqcoOsJGlEPTBiPTCwMlM5KM7:TT6= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDByOUWyNUc,OjhyMEm1NlE9N2F-
HEK293T cells NIT1N4xHfW6ldHnvckBie3OjeR?= NVfEWog{OSCqch?= MVvJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tj\XSjIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKGi{IHL5JGxENU2VL13TJIFv[Wy7c3nzMEBKSzVyIE2gNE41OiEQvF2u MoTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
HEK293T cells M{DyNmZ2dmO2aX;uJIF{e2G7 M2KwfFEhcHJ? MUjJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tl\Wy2YTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOSCqcjDifUBNSy2PUz;NV{BidmGueYPpd{whUUN3MDC9JFEvPTNizszNMi=> NUXiTm16RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
HEK293T cells NX3Kc|hJTnWwY4Tpc44h[XO|YYm= M33S[VEhcHJ? MYTJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tidHCqYTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOSCqcjDifUBNSy2PUz;NV{BidmGueYPpd{whUUN3MDC9JFIvOzdizszNMi=> M{PnXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
MDA-MB-231 cells NF:wWYtHfW6ldHnvckBie3OjeR?= MojlTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDpcpZie2mxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOzhizszNMi=> MmLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MEK0NFEoRjJ6M{CyOFAyRC:jPh?=
MCF7 cells NYPMdJNQTnWwY4Tpc44h[XO|YYm= MnTiNVAhfU1? Mn;YNUBpeg>? MYjJcohq[mm2aX;uJI9nKEmJRkHSJJBpd3OyaH;yfYxifGmxbjDheEBVgXJzMU[xJJJme2mmdXWgbY4hcHWvYX6gUWNHPyClZXzsd{BifCBzMDD1UUBi\nSncjCxJIhzKGK7IFjv[YNpe3RiM{OyOVghe3SjaX7pcoch[mG|ZXSgbY1ufW6xaHnzeI9kcGWvaXPhcEBidmGueYPpdy=> NYrmZ3NTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
SKOV3 cells MXLGeY5kfGmxbjDhd5NigQ>? NEnU[JMzOCC3TR?= Mkf4NlQhcHK| MWfJcohq[mm2aX;uJI9nKEKGTl[tbY5lfWOnZDDpcpZie2mxbjDpckBpfW2jbjDTT29XOyClZXzsd{BifCB{MDD1UUBi\nSncjCyOEBpenNiaX6gZpkhdWG2cnnn[YwhcW64YYPpc44h[XO|YYm= M3ftblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUKyOFg1Lz5{OUGyNlQ5PDxxYU6=
SKOV3 cells MnPkRY51cW2rZ4LheI9zgSCjc4PhfS=> NGn0dHkzOCC3TR?= Mm[3NlQhcHK| NYnTT|lOSW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONT2[zJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQlTOSk1qdmS3Y3XkJINmdGxibXnndoF1cW:wIHH0JFIxKHWPIHHmeIVzKDJ2IHjyd{BjgSC|Y4LheINpKHexdX7kJIhm[WyrbnegZZN{[Xl? NELGc3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGyNlQ5PCd-MkmxNlI1QDR:L3G+
NB1643 cells M3m2cJFJXFNiYYPzZZk> NGfD[JJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 cells MljpdWhVWyCjc4PhfS=> MWrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NUHWb4VKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 cells NHrscVlyUFSVIHHzd4F6 NF\MdpdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NFXOfZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC cells NIr5TXRyUFSVIHHzd4F6 M2rXdZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz MnHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
J774 cells MXLBcpRqcW6obHHtcYF1d3K7IHHzd4F6 M2XTO|I1KGi{cx?= NEDrPYJCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJGo4PzRiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGxRWy2rbnT1Z4VlKE2FUEGg[ZhxemW|c3nvckBi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVAhRSB|Lkeg{txONg>? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells NYfxWFVqSW62aXnu[oxidW2jdH;yfUBie3OjeR?= NX3RO2RsOjRiaILz M2PscGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhUUx4IHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPS5zIN88UU4> NUmxPHVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NlY3QDBpPkK5O|I3PjhyPD;hQi=>
J774 cells NXu4UY9SSW62aXnu[oxidW2jdH;yfUBie3OjeR?= MYKyOEBpenN? NYPpSGFzSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBLPzd2IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBNWFNvaX7keYNm\CCwaYTybYMhd3irZHWgdJJw\HWldHnvckBi\nSncjCyOEBpenNiYomgS5Jq\XO|IHHzd4F6NCCLQ{WwJF0hQC57IN88UU4> NVfSPW5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NlY3QDBpPkK5O|I3PjhyPD;hQi=>
J774 cells MoW5SpVv[3Srb36gZZN{[Xl? NGnCV5gyOCC3TR?= NX7lUmNyPCCqcoO= Mn\1TY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDtc5V{\SCMN{e0JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCOUGOtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{BifCBzMDD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
Assay
Methods Test Index PMID
Western blot E-cadherin / p-Akt / Akt ; beta-catenin / p-GSK3β / Cyclin D1 ; Bcl-xl / Bax / caspase3 / cleaved caspase-3 ; p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin ; pPKB-S473 29731993 25344912 23251002 20649566
Growth inhibition assay Cell viability 25344912
Immunofluorescence α-SMA / CD31 ; E-cadherin / beta-catenin ; COX-2 / p-NFκB ; FOXO3a 27671604 29731993 18388194
ELISA IL-10 / IL-1β / TNFα / IL-6 22208359
In vivo

LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol (from reference)

Kinase Assay:

[4]

  • kinase assays:

    PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.

Cell Research:

[2]

  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.

  • (Only for Reference)
Animal Research:

[3]

  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 36 mg/mL warmed
(117.13 mM)
Water Insoluble
Ethanol '21 mg/mL

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.

3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02337309 Terminated Drug: SF1126 Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|SignalRX Pharmaceuticals Inc.|University of Southern California July 9 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

Answer:
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

Question 2:
What is the suggested formulation of this compound for mouse injection(i.p.)?

Answer:
It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor